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Aims We sought to investigate the prognostic impact of co-morbid burden as defined by the Charlson Co-morbidity Index
(CCI) in patients with a range of prevalent cardiovascular diseases.
Methods
and results
We searched MEDLINE and EMBASE to identify studies that evaluated the impact of CCI on mortality in patients with
cardiovascular disease. A random-effects meta-analysis was undertaken to evaluate the impact of CCI on mortality in
patients with coronary heart disease (CHD), heart failure (HF), and cerebrovascular accident (CVA). A total of 11
studies of acute coronary syndrome (ACS), 2 stable coronary disease, 5 percutaneous coronary intervention (PCI),
13 HF, and 4 CVAmet the inclusion criteria. An increase in CCI score per point was significantly associated with a great-
er risk of mortality in patients with ACS [pooled relative risk ratio (RR) 1.33; 95% CI 1.15–1.54], PCI (RR 1.21; 95% CI
1.12–1.31), stable coronary artery disease (RR 1.38; 95% CI 1.29–1.48), and HF (RR 1.21; 95% CI 1.13–1.29), but not
CVA. ACCI score of .2 significantly increased the risk of mortality in ACS (RR 2.52; 95% CI 1.58–4.04), PCI (RR 3.36;
95% CI 2.14–5.29), HF (RR 1.76; 95% CI 1.65–1.87), and CVA (RR 3.80; 95% CI 1.20–12.01).
Conclusion Increasing co-morbid burden as defined by CCI is associated with a significant increase in risk of mortality in patients
with underlying CHD, HF, and CVA. CCI provides a simple way of predicting adverse outcomes in patients with car-
diovascular disease and should be incorporated into decision-making processes when counselling patients.
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Introduction
Cardiovascular disease (CVD) is a major cause of morbidity and
mortality, accounting for 30% of all-cause mortality worldwide.1
Given the incidence of CVD and co-morbidity burden increases
with age,2 a significant proportion of patients with CVD are older
with multiple co-morbidities. This affects disease progression and
clinical outcomes and can influence clinical decision-making.3 – 5
Cardiovascular co-morbidities such as hypertension, diabetes, atrial
fibrillation, heart failure, and stroke have an independent association
with increased mortality in patients hospitalized with acute myocar-
dial infarction with increasing numbers of these co-morbidities
particularly associated with poor outcomes.6
While previous studies havemainly focused on cardiovascular co-
morbid conditions, patients with CVD often have a broad spectrum
of non-cardiovascular co-morbidities. It remains unclear, however,
*Corresponding author. Tel: +44 01782 671652, Fax: +44 01782 674467, Email: doctorrashid7@gmail.com
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how clustering of multiple cardiovascular and or non-cardiovascular
chronic conditions influences clinical outcomes. Therefore, there is
a need to understand the impact of co-morbid burden, rather than
focusing on individual co-morbid conditions on clinical outcomes in
patients with prevalent CVD.2
The Charlson Co-morbidity Index (CCI) is a recognized measure
of co-morbid burden7 and quantifies the prognostic impact of 22 co-
morbid conditions based on their number and individual prognostic
impact by means of a score.8 It is a useful tool for estimating
prognosis in patients with multiple coexisting illnesses. Table 1 re-
presents the variables. Although various studies have evaluated
the prognostic value of CCI in predicting outcomes in different co-
horts of patients with CVD, there is no systematic review of the lit-
erature that evaluates the prognostic value of CCI on mortality
across a range of CVDs. In this systematic review, we sought to
investigate the prevalence, and prognostic impact, of co-morbidity
defined by the CCI score in patients with three major CVDs;
coronary heart disease (CHD), heart failure, and cerebrovascular
accident (CVA).
Methods
Study inclusion criteria
We included primary studies that evaluated the prognostic impact of co-
morbid burden defined by CCI in patients with CHD, acute or chronic
heart failure, and CVA. Studies were considered for inclusion and
detailed review if their abstract potentially met all three of the following
criteria:
(1) Primary studies evaluating the impact of co-morbidity defined by
CCI on adverse outcomes in patients with CVD.
(2) CVD was defined by CHD [comprising of patients undergoing
percutaneous coronary intervention (PCI) or stable angina or acute
coronary syndrome (ACS)], or acute or chronic heart failure, or
cerebrovascular disease.
(3) Adverse outcomes included mortality and major adverse cardiac
events (MACE) at any length of follow-up.
We excluded studies that did not have results on outcomes defined by
CCI score, but therewas no restriction on the basis of language of study.
We also excluded expert opinion and editorial reviews. We included
conference abstracts to minimize publication bias.
Search strategy
We searched MEDLINE and EMBASE on July 2015 using the broad
search terms: (‘Charlson co-morbidity index’ OR ‘Charlson index’ OR
‘Charlson co-morbidity score’ OR ‘Charlson score’) AND (‘acute myo-
cardial infarction’ OR ‘acute coronary syndrome’ OR ‘coronary heart
disease’ OR ‘coronary artery disease’ OR ‘stroke’ OR ‘cerebrovascular
disease’ OR ‘cerebrovascular accident’ OR ‘heart failure’ OR ‘cardiac
failure’) AND (‘mortality’ OR ‘death’ OR ‘major adverse cardiovascular
event’ OR ‘major adverse cardiac event’ OR ‘cardiovascular disease’).
The search results were reviewed by two independent investigators
(M.R. and C.S.K.) for studies that met the inclusion criteria, and relevant
reviews were identified. Additional studies were retrieved by checking
the bibliographies of included studies and relevant reviews.
Data extraction
Data were extracted from each study into preformatted tables
generated in Microsoft Word. Data collected included year, country,
number of participants, mean age of participants, percentage of
male participants, participant inclusion criteria, follow-up assessment,
lost to follow-up, and results of association between CCI and out-
comes. With regards to quality assessment, we documented the de-
sign of the study, reliable method of ascertainment of outcomes,
.10% loss to follow-up, and if there was any adjustment for potential
confounders.
Data analysis
Meta-analysis for estimated pooled risk ratios (RR) was performed by
the inverse variance method using a random-effects model on the soft-
ware RevMan 5.3 (Nordic Cochrane Centre, København, Denmark). To
reduce the risk of confounding associated with crude estimates, where
available, we chose to pool the results from the most adjusted model,
whereby results were expressed as pooled relative RR with accompany-
ing 95% confidence intervals (CI). Statistical heterogeneity was assessed
using the I2 statistic, with values of 30–60% representing a moderate
level of heterogeneity.9 For I2 . 50%, we performed sensitivity analysis
by systematic exclusion of studies and evaluated the effect on I2 esti-
mates (see Supplementary material online, Table S1). The primary ana-
lysis evaluated adverse outcomes with incremental increase in CCI, and
secondary analysis was performed by considering higher group of CCI
score vs. lower group of CCI score. In the final analysis, we excluded
studies by the same research group over the same time period where
there was the potential that the same participants were studied more
than once. Where there were similar study participants, we chose the
study with the largest sample size or highest adverse outcome event
rate. We evaluated publication bias through Funnel plots and Egger’s
test where there were .10 studies in the analysis and no evidence of
statistical heterogeneity as the power to detect publication bias was
low for meta-analyses of 10 or fewer studies.10
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Charlson co-morbidity index
Variable Points
Myocardial infarction 1
Congestive heart failure 1
Peripheral vascular disease 1
Cerebrovascular disease 1
Dementia 1
Chronic obstructive pulmonary disease 1
Connective tissue disease 1
Peptic ulcer disease 1
Diabetes mellitus 1 if uncomplicated
2 if end-organ damage
Moderate to severe chronic kidney disease 2
Hemiplegia 2
Leukaemia 2
Malignant lymphoma 2
Solid tumour 2
6 if metastatic
Liver disease 1 if mild
3 if moderate to severe
AIDS 6
21Impact of co-morbidity on mortality
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Table 2 Study design and characteristics of participants
Study ID Study design; Year;
Country
No. of
Participants
Participants with
CCI5 0 (%)
Mean age % Male Description of participants
Bottle 201311 Retrospective cohort study;
2006–2009; UK
288 550 15 177 (5%) 42% of admissions
.75 years of age
61% Participants were emergency admissions for ACS in England
Bar 201112 Retrospective cohort study;
2001–2004; USA
243 88 (36%) NA NA Patients with non-traumatic intra-cerebral haemorrhage presented to
hospital emergency department
Chin 199813 Prospective cohort study;
1993–1994; USA
257 48 (18%) Full cohort 41%
.70 years of age
Full
cohort
47%
Participants were admitted with congestive heart failure to the Brigham
and Women’s Hospital
Chirinos 200614 Prospective cohort study;
1998–2000; USA
305 70 (22%) 64 years 100% Male veterans undergoing coronary angiography at Miami Veterans
Administration Medical Centre
Clarke 201115 Retrospective cohort study;
1998–2004; Canada
824 NA 64 years 69% Consecutive patients followed at a tertiary care specialty ambulatory
heart failure clinic
Eberli 201316 Prospective registries; NA;
international
5559 2041 (36%) NA NA Participants from e-Biomatrix PMR and PMS registries evaluating the
efficacy and safety of biolimus-A9-eluting stent
Erickson 201417 Retrospective cohort study;
1999–2007; USA
1202 NA 64 years 65% Participants from ACS registry from a large university hospital
Fabbian 201318 Retrospective cohort study;
1999–2009; Italy
88 014 NA 71 years 48% Participants from database of Emilia-Romagna region, Italy who
presented with first event of myocardial infarction
Goldstein 200419 Prospective cohort study;
1995–1997; USA
960 212 (22%) 68 years NA Participants admitted with ischaemic stroke, Department of Veterans
Affairs (VA) Stroke Study
Hong 201120 Prospective cohort study;
2006–2008; international
675 NA 83 years 58% Octogenarian participants from Sirolimus-eluting coronary stent
(e-Select) registry
Huang 201521 Retrospective; 2002–2011;
Taiwan
798 328 315 556 (39%) 45% ≥65 years 57% Participants with disabilities from the National Health Insurance
Research Database published by the Ministry of Health andWelfare
in Taiwan
Jeger 201422 Retrospective; 2005–2012;
Switzerland
1909 NA 65 years 78% Participants from AMIS plus registry
Jong 200223 Retrospective; 1994–1997;
Canada
38 702 15 020 (38%) 85% ≥65 years 49% Participants from Canadian institute for health information database
admitted with first diagnosis of heart failure
Khawaja 201424 NA; 2008–2013; USA 383 37 (9%) NA NA Patients with primary intra cerebral haemorrhage
Mamas 201525 Post hoc analysis of prospective
registry; 2008–2013;
international
3 067 787 (25%) 64 years 78% Participants were in the Nobori 2 study who underwent Nobori
biolimus-eluting stent implantation
Menendez-Colino
201326
NA; Spain 652 NA 85 years NA Patients admitted with heart failure in six Spanish hospitals
Munoz-Rivas 200927 Retrospective cohort study;
2005–2007; Spain
270 NA 78 years 42% Patients with chronic heart failure diagnosis
Nu´n˜ez 200428 Prospective cohort study;
2000–2003, Spain
1035 481 (46%) 70 years 70% Patients admitted with diagnosis of acute myocardial infarction
Oudejans 201229 Prospective cohort study;
2003–2007; Netherlands
93 0 83 years 37% Patients with diagnosis of heart failure
2
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Perez-Barquero
201030
Retrospective cohort study;
2000–2001; Spain
2127 NA 77 years 43% Patients admitted with heart failure to various hospitals in Spain
Radovanovic 201431 Prospective cohort study;
2002–2012; Switzerland
29 620 15 754 (51%) 64 years 73% Participants from AMIS plus registry
Ramirez-Marrero
201132
Retrospective cohort study;
2004–2005; Spain
715 NA 66 years NA Patients admitted with diagnosis of non-ST-elevation acute coronary
syndromes
Ramirez-Marrero
201333
Retrospective cohort study;
2008–2009; Spain
146 NA 78 years 63% Patients undergoing percutaneous coronary revascularization
Rodriguez-Pascual
201234
Prospective cohort study;
2006–2009
581 121 (20%) 86 years 33% Patients admitted to an acute geriatric unit with decompensated heart
failure
Sachdev 200435 Prospective cohort study;
1985–1989; USA
1471 810 (55%) 60 years 72% All patients undergoing initial coronary angiography for symptoms of
chronic CAD and found to have significant disease (≥75% stenosis)
in one or more coronary arteries
Sanchis 201136 Prospective cohort study;
2002–2009; Spain
1017 NA 68 years 66% Patients admitted with diagnosis of non-ST-elevation acute coronary
syndromes
Schmidt 201237 Retrospective cohort study;
1984–2009; Denmark
234 331 164 937 (70%) 75 years 62% Patients from nationwide Danish cohort registry admitted with
myocardial infarction
Singh 201138 Prospective cohort study;
2005–2008; USA
629 NA 75 years 69% Patients undergoing PCI at the Mayo Clinic in Rochester, NY, USA
Subramanian 200739 Prospective cohort study;
unclear; USA
494 NA 68 years NA Participants from Veterans Affairs outpatients with diagnoses of
congestive heart failure
Teng 201440 Prospective cohort study;
2000–2009; Australia
17 379 105 (0.6%) 70 years 58% Participants were Aboriginal and non-Aboriginal patient with first heart
failure hospitalization
Testa 200941 Prospective cohort study;
1992–2003; Italy
1268 NA 74 years 43% Participants from ‘OsservatorioGeriatrico Regione Campania’ with and
without heart failure
Theuns 201142 Prospective; 1999–2008;
international
463 NA 62 years 75% Participants from two ICD registries from Rotterdam and Basel
Tuttolomondo
200843
Retrospective; 1988–1998; Italy 1878 0 77 years 49% Participants from GIFA registry
Urban 201144 Prospective cohort study;
2006–2008; international
15 147 NA 62 years 75% Participants from Sirolimus-Eluting Coronary Stent implantation study
(e-Select) registry
Van Wijk 201345 Post hoc analysis of RCT;
unclear; international
499 NA NA NA Participants from heart failure study randomized to intensified
NT-proBNP-guided vs. symptom-guided therapy
NA, not available or not reported.
2
3
Im
p
act
o
f
co
-m
o
rb
id
ity
o
n
m
o
rtality
Downloaded from https://academic.oup.com/ehjqcco/article-abstract/3/1/20/2928168 by Liverpool John Moores University user on 24 September 2018
Results
Description of included studies
A total of 3511–45 studies met the inclusion criteria. The process of
study selection is shown in Figure 1. The details of the studies’ design
and participants are described in Table 2. The included studies com-
prised 14 retrospective cohort studies,11,12,15,17,18,21–23,27,30,32,33,37,43
17 prospective cohort studies,13,14,16,19,20,28,29,31,34–36,38–42 1 post hoc
analysis of registry,25 and 1 post hoc analyses of RCT,45while 2 abstract
studies24,26were not clear in reporting the design. There were a total
of 1 538 793 participants in 35 studies. Twenty-four studies reported
a mean age of 71 years and 62% male. The study size varied from 93
participants31 to 798 328 participants.21 The follow-up time ranged
from 30 days to 5 years.
Seventeen studies12–16,19,20,22,23,25,28,29,31,34–36,38,42 reported in-
dividual CCI scores and 530 457 out of 1 538 793 (35%) patients had
no co-morbidities (CCI ¼ 0). The prevalence of each co-morbid
condition in each of the cardiovascular conditions/events studied
is presented in Figure 2. Diabetes and a history of previous myocar-
dial infarction were the two most common conditions present in
patients with CHD. Approximately 10% of the patients with heart
failure had previous history of myocardial infarction (only reported
in 6 studies out of the total 13) and 12% had a history of chronic
obstructive pulmonary disease. Similarly, diabetes was the most
prevalent co-morbidity in the patients with CVA cohort. Haemato-
logical malignancies such as lymphoma leukaemia and AIDS were
the least frequent co-morbid conditions across all the cohorts
studied.
Quality assessment of included studies
The quality of studies included is described in Table 3. There was no
loss to follow-up for 13 of the included studies. Twenty-two studies
had ,10% loss to follow-up. The largest absolute loss to follow-up
was reported by Radovanovic et al. as they excluded 1091 patients
from final results due to unavailability of CCI data.31 Just over half of
the studies12 – 14,18,19,21,24,25,29,35 – 37,39 – 42,44,45 (18 out of 35) re-
ported estimates of associations adjusted for potential confounders.
Results of included studies
The characteristics of patients included in the studies and associ-
ation of CCI score on outcomes are described in Table 4.
Acute coronary syndrome
A total of 11 studies11,17,18,21,22,28,32,33,36,37 evaluated the impact of
co-morbidity in 1 154 408 patients admitted with ACS; however,
only 5 studies11,21,28,31,37 reported on patients with no co-morbidity
(37% of patients had CCI ¼ 0). Five studies17,18,31,32,36 were statis-
tically pooled for the association between an incremental increase
in CCI and mortality (Figure 3A). Among patients with ACS, the
risk of death was significantly greater with incremental increase
in CCI score (RR 1.33; 95% CI 1.15–1.54). Three studies (I2 ¼
96%)11,21,31 compared patients with no co-morbidity (CCI score
of 0) vs. patients with any co-morbidity (CCI score of .0) showing
that the presence of co-morbidity (CCI score of .0) resulted in
almost twice the risk of death (RR 1.93; 95% CI 1.67–2.24). Rado-
vanovic et al.31 and Huang et al.21 also analysed the impact of CCI
score of 0–1 vs. .1 showing a higher risk of death in patients
Figure 1 Flow diagram of study selection.
24 M. Rashid et al.
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with CCI score of .1 (RR 2.26; 95% CI 1.23–4.16; I2 ¼ 98%).
Three studies21,31,37 demonstrated a more than two-fold rise in
mortality in patients with a CCI score of.2 comparing with a score
of 0–2. Only one study16 comparedCCI score of 0–3 vs..3, which
reported higher mortality (RR 5.89; 95% CI 5.56–6.24) in patients
with more co-morbidities (CCI score of .3).
Figure 2 Charlson co-morbidity individual component distribution.
25Impact of co-morbidity on mortality
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In an ACS registry (AMIS registry), Jeger et al.22 reported an in-
creased risk of MACE (a composite endpoint of re-infarction,
CVA, and/or death) over a 1-year follow-up period in patients
with CCI score of ≥2. In another study, Nu´n˜ez et al.28 demon-
strated that a higher CCI score was an independent predictor of
mortality or acute myocardial infarction at 30 days and 1 year.
Stable coronary heart disease
Two studies14,35 studied the relationship between incremental rise
in CCI score and mortality in patients with stable CHD (Figure 3B),
suggesting that incremental increases in CCI score were associated
with worse outcomes (RR 1.38; 95% CI 1.29–1.48; I2 ¼ 0%).
Sachdev et al.35 also reported that patients with a CCI score of 0
have better long-term survival (RR 1.88; 95% CI 1.48–2.38). They
also reported that almost half of the patients (49%) included in
the cohort were disease free and had no co-morbidities (CCI ¼ 0).
Patients undergoing percutaneous coronary intervention
Lastly, five studies16,20,25,38,44 reported impact of CCI on long-term
survival in patients undergoing PCI, out of which four indicated that
mortality increases with each point rise in CCI score (RR 1.21; 95%
CI 1.12–1.31; I2 ¼ 71%) (Figure 3C). Only Mamas et al.25 reported
about patients with no co-morbidities in their study.
Heart failure
A total of 13 studies reported the influence of co-morbidity in 63
609 patients with an underlying diagnosis of heart failure. An in-
creased risk of mortality (RR 1.21; 95% CI 1.13–1.29; I2 ¼ 48%)
was observed per point increase in CCI score among four stud-
ies.13,15,26,41 Jong et al.23 and Rodriguez-Pascual et al.34 compared
patients with CCI score of 0–1 vs. .1 and demonstrated that a
CCI score of .1 was associated with an increased risk of death
(RR 1.60; 95% CI 1.52–1.70; I2 ¼ 0%). Similar trends were observed
in studies that compared a CCI score of .2 with a CCI score of 0–
2. For instance, three studies23,29,30 reported an increased risk of
death (RR 1.76; 95% CI 1.65–1.87; I2 ¼ 0%) in patients with CCI
score of.2. Patients with high burden of co-morbidities (CCI score
of .4) were analysed in three studies,29,34,42 which showed almost
three-fold increase in relative risk of mortality (RR 2.93; 95% CI
1.99–4.31; I2 ¼ 15%). Two studies27,45 reported increased risk of
death with higher co-morbid burden with hazard ratio of .1, but
it was unclear how they are related to CCI score. Both studies
Figure 2 Continued.
26 M. Rashid et al.
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Figure 3 Acute coronary syndrome patients, stable angina/stable coronary heart disease patients, and patients undergoing percutaneous cor-
onary intervention and mortality according to Charlson Co-morbidity Index. (A) Acute coronary syndrome. (B) Stable angina/stable coronary
heart disease. (C ) Patients undergoing PCI.
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Table 3 Quality of included studies
Study ID Prospective
study design
Reliable ascertainment of outcomes Less than 10% loss to
follow-up
Use of adjustments for potential confounders
Bottle 201311 No;
retrospective
Yes; death from death certificates from the Office for National Statistics Unclear None
Bar 201112 Yes; prospective Unclear; outcome assessed using modified Rankin scale out to 12 months
by unclear methods
Unclear Adjusted for presence of IVH, infratentorial ICH, and use of early
DNACPR orders
Chin 199813 Yes; prospective Yes; death from chart review, survey of families, and search of the National
Death Index
Yes; 7 patients discharged
quickly and unreachable,
5 too sick for interview
White ethnicity, age ≥70 years, prior congestive heart failure, chronic
pulmonary disease, Charlson Co-morbidity Index score, third heart
sound, serum sodium ≤135, EF ,0.50, diabetes, respiratory rate
.30/min, cardiomegaly on admission chest radiograph
Chirinos 200614 Yes; prospective Yes; patients’ interview and review of hospital electronic records Yes; 9 patients were lost to
follow-up
Multivariate analysis adjustments for age, left ventricular ejection
fraction, congestive heart failure, and number of coronary artery
territories involved with haemodynamically significant lesions
Clarke 201115 No;
retrospective
Yes; electronic database, review of medical notes, clinic visits, and review of
death certificates
Yes; none None
Eberli 201316 Yes; prospective Unclear; 1-year all-cause and cardiac mortality by unclear method Unclear None
Erickson 201417 No;
retrospective
Yes; 6-month post-discharge all-cause mortality or secondary
cardiovascular events or revascularization procedures
Yes; none None
Fabbian 201318 No;
retrospective
Yes; in-hospital mortality for myocardial infarction Yes; none Chronic kidney disease
Goldstein 200419 Yes; prospective Yes; death at discharge and 1-year mortality Yes; none Initial stroke severity
Hong 201120 Yes; prospective Yes; followed up at 30, 180, and 360 days by telephone communication,
office visit, or by contacts with primary physicians or referring
cardiologists for 1-year mortality, stent thrombosis
Yes; none Unclear
Huang 201521 No;
retrospective
Yes; data collected fromNational Health Insurance Research Database and
the National Disability Registration Database of Taiwan
Yes; none Adjusted (Model A); variables unclear
Jeger 201422 No;
retrospective
Yes; data collected from AMIS plus registry Yes; 161 lost to follow-up None
Jong 200223 No;
retrospective.
Yes; 30-day and 1-year mortality ascertained by linking the database with
Ontario registered person database
Yes; none None
Khawaja 201424 Unclear Unclear; primary outcomes of modified Rankin scale of 4–6, death and
poor discharge disposition (any disposition other than home or
inpatient rehabilitation) assessed by unclear methods
Unclear Adjusted for baseline ICH score
Mamas 201525 Yes; prospective Yes; data was collected into aWeb-based data management system and an
independent clinical events committee adjudicated all events
No; 326 lost to follow-up at
5 years
Adjusted for baseline demographic and lesion characteristic variables
with a P-value of ,0.05
Menendez-Colino
201326
Unclear Unclear; mortality at 12 months; unclear follow-up methods Yes; 25 patients Unclear
Munoz-Rivas 200927 No;
retrospective
Unclear Unclear Unclear
Nu´n˜ez 200428 Yes; prospective Yes; 30-day and 1-year mortality or reinfarction at outpatient follow-up
and telephonic contact
Yes; none None
Oudejans 201229 Yes; prospective Yes; all-cause mortality within 3 years; follow-up information obtained
from hospital information system or from patient’s general practitioners
Yes; 1 patient was lost to
follow-up
Age, gender, LVEF, and NT-proBNP
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Perez-Barquero
201030
No;
retrospective
Unclear; in-hospital mortality by unclear follow-up methods Unclear Unclear
Radovanovic 201431 Yes; prospective Yes; data collected from AMIS plus registry No; 1091 patients’ CCI data
were not available
None
Ramirez-Marrero
201132
No;
retrospective
Unclear Yes; none None
Ramirez-Marrero
201333
No;
retrospective
Yes; cardiovascular mortality during follow-up Yes; none None
Rodriguez-Pascual
201234
Yes; prospective Unclear; mortality Unclear None
Sachdev 200435 Yes; prospective Yes; patients were followed up at 6 months, 1 year, and then annually by a
mailed questionnaire, with telephone backup, as well as a National
Death Index search for non-responders through December 2000
Yes; none Adjusted for age, unclear if other variables were adjusted
Sanchis 201136 Yes; prospective Yes; data collected from admission records and follow-up Yes; 4 patients did not
complete follow-up
Adjusted for variables with P, 0.05 but variables unclear
Schmidt 201237 No;
retrospective
Yes; standardized incidence rate of myocardial infarction and 30-day and
31- to 365-day mortality by sex
Unclear Age and sex
Singh 201138 Yes; prospective Yes; all-cause mortality during follow-up; the second main outcomewas MI
defined as the presence of 2 of 3 following criteria: prolonged
(.20 min) ischaemic chest pain and elevation of cardiac biomarkers
(creatinine kinase-MB or relative index) more than two times upper
limit of normal, or electrocardiographic changes (ST/T-wave changes or
new Q waves)
Yes; 2% participants lost to
follow-up
None
Subramanian 200739 Yes; prospective Yes; 5-year mortality during follow-up data obtained from Veterans
Integrated Health Systems Technology Architecture databases
Yes; 35 patients were
excluded for missing
values
Adjusted; variables unclear
Teng 201440 Yes; prospective Yes; data were collected from the Hospital Morbidity Data Collection,
which is linked to the Mortality register
Unclear Adjusted; variables unclear
Testa 200941 Yes; prospective Yes; all subjects were contacted at home or in their institution and
examined by physicians trained to administer a questionnaire
Yes; 35 patients were
unreachable and 9 did
not have social support
Age, sex, heart rate, systolic blood pressure, diastolic blood pressure,
social support, drugs number, MMSE, BADL, NYHA, CAD, chronic
obstructive pulmonary disease, neurological disease, congestive
heart failure, and CCI
Theuns 201142 Yes; prospective Yes; the data collected from two prospective ICD registries from
Rotterdam and Basel; patient followed up at outpatient clinics
Yes; none Adjusted for age
Tuttolomondo
200843
Yes; prospective Yes; demographic data and follow-up were collected from GIFA registry Yes; none None
Urban 201144 Yes; prospective Yes; the data collected from the e-Select registry where patients were
followed up at 30, 180, and 360 days by telephone communication or
office visit by contacts with primary physicians or referring cardiologist
Unclear Adjusted for variables with entry P-value of 0.10 and stay criterion of
0.15; unclear exact variables
Van Wijk 201345 Yes; prospective Yes; clinically followed up for 18 months with recording of hospitalization,
mortality, and adverse events up to 5 years
Unclear Adjusted; variables unclear
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Table 4 Follow-up and results of the association between Charlson Co-morbidity Index and outcome
Study ID Type of population
(CAD, HF, CVA)
Definition of CCI Outcome and duration of follow-up Results demonstrating association between CCI and outcome
Bottle 201312 ACS (CAD) Charlson score 0 vs. .0 30-day mortality 30-day mortality: CCI score 0: 8370/151 577 (5.5%); CCI score .0: 20 999/177 792
(11.8%)
Bar 201111 Stroke (CVA) Incremental rise in CCI from
0 to .3
12-month functional outcome according to
modified Rankin scale
CCI score 1: OR 1.78 (0.86–3.70); CCI score 2: OR 2.34 (0.98–5.61); CCI score 3: OR
3.48 (1.64–7.37)
Chin 199813 HF Incremental increase in CCI Time to mortality Mortality per CCI point to max of 4 points: HR 1.3 (1.1–1.4)
Chirinos 200614 Stable CAD Incremental increase in modified
CCI
All-cause mortality during 58-month
follow-up
Odds of mortality with incremental increase in modified CCI score: OR 1.32
(1.17–1.48)
Clarke 201115 Heart failure (HF) Incremental increase in CCI Time to mortality with follow-up of mean of
4.4 years
Overall mortality by per unit increase in CCI: HR 1.26 (1.19–1.35)
Eberli 201316 PCI (CAD) Mortality by different CCI score 1-year mortality and cardiac mortality Overall 1-year mortality: CCI score 0: 18/2041 (0.9%); CCI score 1: 28/2162 (1.3%);
CCI score 2: 18/776 (2.3%); CCI score ≥3: 25/578 (4.3%)
Cardiac mortality: CCI score 0: 14/2041 (0.7%); CCI score 1: 13/2162 (0.6%);
CCI score 2: 9/776 (1.2%); CCI score ≥3: 14/578 (2.4%)
Erickson 201417 ACS (CAD) Incremental increase in CCI Inpatient and 6-month mortality and
post-discharge cardiac event or
procedure
Inpatient death with CCI: OR 1.28 (1.14–1.43)
6-month death with CCI: OR 1.55 (1.41–1.72)
Post-discharge cardiac event or procedure CCI: 1.21 (1.12–1.31)
Fabbian 201318 ACS (CAD) Incremental increase in CCI In-hospital mortality from MI In-hospital mortality for MI with CCI without renal dysfunction: OR 1.101
(1.069–1.134)
Goldstein 200419 Stroke (CVA) Low CCI 0–1 vs. high CCI ≥2 1-year mortality 1-year mortality with low CCI score 0–1: 88/551 (16%)
High CCI score ≥2: 106/429 (26%)
Hong 201120 PCI (CAD) Incremental rise in CCI on
outcomes
Time to mortality or stent thrombosis with
follow-up up to 1-year
Every 1-point increment in CCI on death: HR 1.3 (1.1–1.5)
Every 1-point increment on stent thrombosis: HR 1.5 (1.3–1.8)
Huang 201521 ACS (CAD) Risk for each CCI score Time to acute myocardial infarction Adjusted model A (unclear variables): CCI score 1: HR 2.25 (2.12–2.39); CCI score 2:
HR 3.07 (2.89–3.26); CCI score 3: HR 3.71 (3.48–3.95); CCI score ≥4: HR 5.89
(5.56–6.25)
Jeger 201422 ACS (CAD) Charlson score ≥2 1-year MACE 1-year MACE with CCI score ≥2: OR 1.42 (1.05–1.92)
Jong 200223 Heart failure (HF) CCI score and mortality rate 30-day and 1-year mortality CCI score 0: 30-day mortality 1397/15 020 (9.3%); 1-year mortality 4025/15 020
(26.8%)
CCI score 1: 30-day mortality 1348/12 602 (10.7%); 1-year mortality 3907/12 602
(31.0%)
CCI score 2: 30-day mortality 895/6485 (13.8%); 1-year mortality 2555/6485 (39.4%)
CCI score 3: 30-day mortality 864/4595 (18.8%); 1-year mortality 2325/4595 (50.6%)
Khawaja 201424 Stroke (CVA) Incremental increase in CCI
score
Death at unclear follow-up Death and CCI score: OR 1.05 (0.91–1.21)
Mamas 201525 PCI (CAD) Incremental increase in CCI
score
30-day, 1-year, and 5-year cardiac death and
MACE
30-day: cardiac death: OR 1.47 (1.20–1.80); MACE: OR 1.27 (1.11–1.44)
1-year: cardiac death: OR 1.46 (1.30–1.65); MACE: OR 1.32 (1.23–1.42)
5-year: cardiac death: OR 1.38 (1.24–1.53); MACE: OR 1.29 (1.22–1.36)
Menendez-Colino
201326
Heart failure (HF) CCI score and mortality Time to mortality with follow-up maximum
of 12 months
CCI score: HR 1.13 (1.04–1.24)
Munoz-Rivas 200927 Heart failure (HF) Incremental increase in CCI Survival Survival with incremental CCI: HR 1.46 (1.21–5.07)
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Nu´n˜ez 200428 ACS (CAD) CCI score and risk compared
with CCI score 0
Time to death or reinfarction to a maximum
of 30 days and 1 year
Risk of death or reinfarction at 30 days: CCI score 1: HR 1.00; CCI score 2: HR 1.69
(1.10–2.59); CCI score 3: HR 1.78 (1.08–2.92); CCI score 4: HR 1.57 (0.87–2.83)
Risk of death or reinfarction at 1 year: CCI score 1: HR 1.00; CCI score 2: HR 1.62
(1.18–2.23); CCI score 3: HR 2.00 (1.39–2.89); CCI score 4: HR 2.24 (1.50–3.36)
Oudejans 201229 Heart failure (HF) CCI score 0–2 vs. 3–4 or ≥4 Time to mortality to a maximum of 3 years 3-year mortality: CCI score 0–2: HR 1.00; CCI score 3–4: HR 1.5 (0.7–2.9); CCI
score .4: HR 4.0 (1.9–8.8)
Perez-Barquero
201030
Heart failure (HF) CCI score 1–2 vs. ≥3 In-hospital mortality In-hospital mortality: CCI score 1–2: 76/1528; CCI score ≥3: 48/599
Radovanovic 201431 ACS (CAD) Incremental rise in CCI and risk
compared with CCI score 0
In-hospital mortality and 1-year mortality
assessed using data from AMIS plus
registry
In-hospital mortality compared with CCI score 0: CCI score 1: OR 1.36 (1.16–1.60);
CCI score 2: OR 1.65 (1.38–1.97); CCI score ≥3: OR 2.20 (1.86–2.57)
1-year mortality per CCI point: age-adjusted mortality: OR 1.44 (1.36–1.53)
Ramirez-Marrero
201132
ACS (CAD) Higher CCI treated as
incremental
In-hospital mortality and median follow-up of
24 months
In-hospital mortality: OR 1.6 (1.4–1.8); long-term mortality: OR 1.3 (1.2–1.5);
readmission for HF: OR 1.2 (1.04–1.3); MACE during follow-up: OR 1.1 (1–1.2)
Ramirez-Marrero
201333
ACS (CAD) Highest CCI score Cardiovascular mortality during follow-up of
36 months
CCI and long-term mortality: OR 1.72 (1.09–2.71)
Rodriguez-Pascual
201234
Heart failure (HF) CCI score Mortality Mortality by CCI score: 0–1: 5/121; 2–4: 17/227; ≥5: 26/194
Sachdev 200435 Stable CAD CCI scores of 0, 1, and ≥2 Time to mortality during follow-up period of
almost 11 years
CCI score 0: 95/810 (11.7%); CCI score 1: 58/378 (15.3%); CCI score ≥2: 88/283
(31.1%)
Incremental increase in modified CCI: HR 1.41 (1.30–1.53)
Sanchis 201136 ACS (CAD) Incremental increase in CCI per
point
Time to mortality to a maximum of 1 year Per point increase in CCI: HR 1.3 (1.2–1.4)
Schmidt 201237 ACS (CAD) CCI score 0 (normal) vs. ≥3
(very severe)
30-day and 31- to 365-day mortality 30-day mortality: RR 1.96 (1.83–2.11)
31- to 365-day mortality: RR 3.89 (3.58–4.24)
Singh 201138 PCI (CAD) Incremental increase in CCI per
point
Time to mortality or myocardial infarction
during median follow-up of 35 months
Death during follow-up: HR 1.12 (1.06–1.18)
Death/MI during follow-up: HR 1.05 (1.01–1.10)
Subramanian 200739 Heart failure (HF) Incremental increase in 3 points
of CCI
Time to mortality at follow-up of up to 5
years
5-year all-cause mortality: HR 1.39 (1.16–1.67)
Teng 201440 Heart failure (HF) CCI unclear if incremental or
cut-off
1-year mortality 1-year mortality with CCI: ,55 years: HR 1.38 (1.26–1.51); ≥55 years: HR 1.20
(1.18–1.22)
Testa 200941 Heart failure (HF) Incremental increase in CCI
score
Time tomortality to amaximum follow-up of
12 years
12-year mortality with CCI: HR 1.15 (1.01–1.31)
Theuns 201142 Heart failure (HF) CCI score .5 Time to all-cause mortality during a median
follow-up of 30.5 months
All-cause mortality: HR 3.49 (2.06–6.60)
Tuttolomondo
200843
Stroke (CVA) CCI score ,2 vs. CCI score .2 In-hospital mortality In-hospital mortality: OR 35.7 (4.8–265.2)
Urban 201144 PCI (CAD) Incremental increase in CCI per
point
Time to death, stent thrombosis, and major
bleeding at maximum of 1 year
1-year death: HR 1.2 (1.1–1.2)
1-year stent thrombosis: HR 1.2 (1.1–1.4)
1-year major bleeding: HR 1.1 (1.0–1.2)
Van Wijk 201345 Heart failure (HF) Incremental increase in CCI
score
Hospital-free survivals during follow-up
period
CCI score: HR 2.47 (1.27–4.83)
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were only available in abstract form and, therefore, not included in
the final meta-analysis. More interestingly, Subramanian et al.39 as-
sessed the impact of incremental increase in CCI per 3 points in heart
failure patients over 5 years, reporting increased risk of death (HR
1.39; 95% CI 1.16–1.67) with growing burden of co-morbidities.
Cerebrovascular accident
A total of four studies analysed the impact of CCI score on survival
in patients with an acute CVA. Khawaja et al.24 reported a no signifi-
cant increased risk of death with incremental increase in CCI score
(RR 1.05; 95% CI 0.91–1.21). However, higher CCI score (.2)
had significant impact on mortality (RR 3.80; 95% CI 1.20–12.01;
I2 ¼ 84%) when compared with low CCI score (0–2).
Discussion
In this study, we evaluated the prevalence and prognostic impact of
co-morbidities as defined by CCI in patients with CHD, heart fail-
ure, and CVA. We observed a significant burden of co-morbidity
in patients with CVD—two-thirds of patients included in the ana-
lysis had at least one chronic condition. The most common cardio-
vascular co-morbid conditions identified in patients with CHDwere
diabetes and history of prior myocardial infarction, whereas chronic
obstructive pulmonary disease and kidney disease were the most
frequent non-cardiovascular conditions. To our knowledge, this is
the first study to systematically show the impact of co-morbid bur-
den as defined by CCI on survival in patients with CHD, heart
failure, and CVA. We found that the presence of co-morbidities
had a significant incremental prognostic impact in patients with a
broad range of CVDs.
CHD is the commonest CVD affecting one in seven people in
USA46 and UK every year. Patients with CHD are likely to have high-
er number of coexisting illnesses either in the form of prevalent
cardiovascular risk factors such as diabetes and hypertension or in
the form of direct manifestations of CHD such as prior myocardial
infarction or heart failure. For instance, in one study, diabetes,
hypertension, and heart failure were found to be most frequently
encountered coexisting illnesses in patients admitted with ACS
and 68% of the participants had at least three co-morbidities.47
The rising burden of co-morbidity has been reported to have
inverse relationship with survival outcomes in patients with CHD.
In our analysis, incremental rise in CCI was associated with signifi-
cant increase in mortality and the risk of death was almost doubled
with the presence of any co-morbidity compared with the patients
with no co-morbidity (Figure 3A). This has important clinical implica-
tions in this cohort of patients as the prevalent cardiovascular risk
factors such as hyperlipidaemia, smoking, and other related cardio-
vascular co-morbidities such as hypertension and diabetes in
patients with CHD are usually treated aggressively, but there is
growing evidence that non-CVD burden may also contribute to
increased risk of mortality.25,31 We report that CCI is not only a
simple way of quantifying co-morbid burden but also provides prog-
nostic value in ascertaining outcomes. Clinicians often use risk as-
sessment tools such as GRACE and TIMI scores in determining
Figure 3 Continued.
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the type of intervention, treatment plan, and allocation of resources
in managing patients with ACS. Although these models have been
validated in predicting the adverse events,48,49 the clinical data incor-
porated in these models do not take into account the co-morbid
burden of the patients. Previous studies have suggested that the
performance of such risk models improves when co-morbidity
scores such as CCI are added to the risk scores17 and may help in
better allocations of resources and developing robust treatment
pathways for patients with multiple co-morbidities. Our study high-
lights the importance of taking into consideration of the overall co-
morbid burden in such patients while making the therapeutic
decisions. Furthermore, our study also demonstrates that co-
morbidity burden has prognostic value.
The prevalence of heart failure is increasing due to the ageing
population and better survival from acute cardiac events.50 Our
findings reinforce the hypothesis that heart failure patients with
multiple co-morbidities have worse outcomes.15 Similarly, increas-
ing co-morbid burden is associated with a worse prognosis in
patients after an acute cerebrovascular event. We observed that
the risk of death was almost four-fold greater in patients with two
or more coexisting illnesses (Figures 4 and 5).
The mechanism by which the coexisting co-morbid burden influ-
ences outcomes in patients with CVD is complex and multifactorial.
Older and frailer patients with high burden of co-morbidities are
more likely to be treated conservatively following a cardiovascular
event.51,52 For instance, a large national ACS registry reported an
incremental reduction in provision of evidence-based treatments
such as aspirin, statins, angiotensin-converting enzyme (ACE) inhibi-
tors, and reperfusion therapy to the older multi-morbid patients.53
In another recent analysis of 18 814 patients, Patel et al. identified
that patients with higher co-morbid burden as defined by CCI
were less likely to receive coronary artery angiography and/or re-
vascularization following presentation with ST-segment elevation
myocardial infarction.54 Similarly, thrombolysis therapy in acute
ischaemic stroke is usually reserved for younger patients with no
significant burden of co-morbidities due to fear of less favourable
outcomes such as bleeding complications in elderly patients with
multiple co-morbidities.55 In the management of patients with
chronic heart failure, the associated burden of co-morbidities may
limit the use of medications such as ACE inhibitors or spironolac-
tone, particularly in patients with severe chronic kidney disease56
and b-blockers in patients with coexisting severe chronic obstruct-
ive pulmonary disease. Furthermore, patients with multiple chronic
conditions are less likely to receive invasive therapies such as im-
plantable cardioverter-defibrillators or cardiac resynchronization
therapy.57 There is also growing evidence that increasing burden
of co-morbidities in patients with heart failure is associated with re-
peated hospitalization and poor outcomes.58,59
Provision of aggressive treatment strategies in patients with multi-
morbidity can lead to higher incidence of complications and adverse
outcomes. For example, patients with leukaemia are at higher risk of
stent thrombosis60 and those with liver dysfunction are at increased
Figure 4 Heart failure patients and mortality according to Charlson Co-morbidity Index.
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risk of bleeding complications post-PCI and cardiac mortality.61
Similarly, the presence of diabetes and haematological disorders
has been shown to increase the risk of haemorrhagic transformation
in patients with ischaemic stroke.62,63 Consequently, the presence
of coexisting diseases may drive poor outcomes in patients with
CHD due to reduced scope of treatment options and increased
risk of complications. Hence, clinicians may be reserved in deciding
treatment strategies while managing patients with multi-morbidity
due to the challenge of finding a balance between risk and benefit
of an intervention.64,65
Other factors that may be responsible for deleterious effect of
co-morbidities on survival outcomes are the presence of coexisting
illness sharing the same pathophysiology and adverse drug reactions
due to polypharmacy. For example, the presence of anaemia results
in low cardiac output state and has been reported to have synergetic
impact on the mortality in patients with chronic heart failure.66
Our findings have important implications in the management of
patients with CHD, heart failure, and cerebrovascular disease.
Treatment options such as medical therapies, PCI, surgical revas-
cularization, device therapies, and thrombolysis are now readily
available to wider spectrum of patients. Although international
guidelines67,68 advocate a comprehensive assessment of patients
taking into account their co-morbid status, contemporary risk strati-
fication tools such as GRACE, Cath PCI, and Syntax are derived
from data sets based on patient’s characteristics, procedural demo-
graphics, and cardiovascular risk factors and do not take into
account patients’ co-morbid burdens. Our analysis shows that
CCI score has prognostic value in our cohort of patients and using
CCI alongside these risk models can help physicians to ascertain
outcomes and better resource allocation. For instance, the addition
of CCI to the Mayo Clinic Risk Score for PCI increased net re-
classification index by 34% and improved the c-statistic for the mod-
el significantly.38 Erickson et al.17 also tested the risk prediction of
GRACE model by adding CCI and observed a significant improve-
ment in predicting outcomes in ACS patients. Another study re-
ported improved discriminative performance of GRACE Risk
Prediction Index score when added with CCI in predicting future
cardiac-related events post-myocardial infarction.17 Therefore, the
assessment of co-morbid status and its impact on long-term survival
should be integrated into the counselling of the patients before
deciding the choice of treatment in conjunction with traditional
risk assessment.
Our study has several strengths and limitations. To our knowl-
edge, this is the first review on impact of co-morbidity defined by
CCI on major CVD such as CHD, heart failure, and cerebrovascular
disease.Wewere able to analyse the impact of per unit rise in CCI in
our cohort of patients demonstrating that rise in CCI score has in-
verse relationship with survival. We were also able to evaluate the
impact of CCI among individual cohorts of CHD namely stable an-
gina, ACS, and those undergoing PCI and found a uniform negative
impact of rising CCI score across all cohorts. Additionally, we also
studied the prevalence of co-morbidities in patients with CVD and
found that majority of patients in this cohort have significant burden
of co-morbidities.
Our study was limited by the incomplete reporting of original
studies and was reliant on the published data available. We were
not able to evaluate the impact of individual components of CCI
on mortality, as this was not consistently reported across all studies.
Furthermore, the studies included in our review were mainly obser-
vational, which have their own inherent limitations and may be
subject to selection biases and unmeasured confounders. Another
limitation is that we found significant heterogeneity in several ana-
lyses. This may be because many of the studies are large with very
narrow confidence intervals leading to statistical heterogeneity
when there is little overlap in 95% CI among the studies. However,
all the studies, in general, report estimates that are consistently sig-
nificant and favour increased events with higher CCI score. The stat-
istical heterogeneity arises from differences in each study in terms of
population evaluated and study methodology, which leads to vari-
ation in estimates for the prognostic value of CCI.
Conclusion
Our study shows that co-morbid burden defined by CCI is signifi-
cant across a broad range of cardiovascular conditions and has
significant impact on survival in patients with CHD, heart failure,
Figure 5 Cerebrovascular accident patients and mortality according to Charlson Co-morbidity Index.
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and CVA. Assessment of co-morbid burden using CCI provides a
method of quantifying risk associated with co-morbidities in patients
with CVD and should be incorporated into decision-making
processes when counselling patients regarding risk and benefits of
treatment in conjunction with allocation of resources.
Supplementary material
Supplementary material is available at European Heart Journal –
Quality of Care and Clinical Outcomes online.
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